---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-004324"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:45:17.089451+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Arbutus Q2 net loss $19.8M; cuts workforce 40%, extends cash runway to Q4 2026

## Summary
- Net loss of $19.8M ($0.11 loss per share) vs $17.1M loss prior year; revenue $1.7M down from $4.7M.
- Workforce reduction of 40% (discontinuing HBV discovery); one-time restructuring charge $3-4M in Q3.
- Cash, cash equivalents & investments $148.5M; cash runway extended into Q4 2026 (2024 cash burn guidance $63-67M).
- IM-PROVE I data: 33% of patients achieved undetectable HBsAg; 67% for those with baseline HBsAg <1000 IU/mL.
- LNP litigation vs Moderna trial set for April 21, 2025; Pfizer/BioNTech ongoing.

## SEC filing metadata
- accession: 0001171843-24-004324
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184324004324/0001171843-24-004324-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184324004324/f8k_080124.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-004324
- JSON: https://secwatch.observer/filing/0001171843-24-004324.json
- Plain text: https://secwatch.observer/filing/0001171843-24-004324.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.